The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat

被引:79
作者
Ashburn, MA
Ogden, LL
Zhang, J
Love, G
Basta, SV
机构
[1] Univ Utah, Hlth Sci Ctr, Dept Pharm Practice, Salt Lake City, UT USA
[2] Univ Utah, Hlth Sci Ctr, Dept Anesthesiol, Acute Pain Serv, Salt Lake City, UT USA
[3] Univ Utah, Hlth Sci Ctr, Dept Anesthesiol, Palliat Care Serv, Salt Lake City, UT USA
关键词
transdermal fentanyl; breakthrough pain; opioid analgesic; cancer pain;
D O I
10.1016/S1526-5900(03)00618-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Preliminary reports have demonstrated that the application of local heat to the transdermal fentanyl patch significantly increased systemic delivery of fentanyl. The objective of this study was to further evaluate the pharmacokinetic effect of local heat administration on fentanyl drug delivery through the transdermal fentanyl patch delivery system in volunteers. In addition, the study was intended to document the effect of heat on steady-state transdermal fentanyl delivery. This was an open, 3-period, crossover study that evaluated the pharmacolkinetics and safety of 25 mug/h transdermal fentanyl administered with and without local heat. During Sessions A and B, subjects received transdermal fentanyl for a 30-hour period. During Session A, heat was applied for 1 hour at the 24-hour time point during the 30-hour period. During Session B, heat was applied for the first 4 hours and then again for 1 hour at the 24-hour time point during the 30-hour period. The order of Sessions A and B was randomized, and a minimum of 2 weeks separated the sessions. Five of the 10 subjects returned to participate in Session C. During Session C, subjects received transdermal fentanyl 25 mug/h for 18 hours. Heat was applied during the first 4 hours of administration and then again for 15-minute periods at the 12- and 16-hour time points. Arterial blood samples for determination of serum fentanyl concentration were collected. Maximum concentration (C-max), time to maximum concentration (t(max)), and area under the curve (AUC) were determined for each treatment period. Sedation, vital signs, oxygen saturation, and adverse events were recorded. During a period of 36 hours, there were no significant differences in C-max, AUC, or T-max between transdermal fentanyl delivery with no heat and heat. However, significant differences were seen during the first 4 hours, with Cmax and AUC values almost 3 times higher for the heated administrations than for the administrations without heat. With heat, the mean Cmax was 0.63 ng/mL compared with a C a Of 0.24 ng/mL without heat (P = .007). With early heat, the mean AUC was 1.22 ng/mL (.) h compared with 0.42 ng/mL (.) h without heat (P = .003). There was no statistically significant difference between the median times to achieve peak values (T-max) during the first 4 hours. The addition of heat at 24 hours resulted in rapid increases in serum fentanyl concentrations for both groups and higher serum fentanyl concentrations for the administration that did not receive heat previously. Applying heat for 15 minutes at the 12-hour and 16-hour time points produced a rapid but short duration increase in serum fentanyl concentrations. The results suggest controlled heat might be used to significantly shorten the time needed to reach clinically important fentanyl concentrations. Controlled heat might be useful to produce rapid increases in serum concentrations for the rapid treatment of breakthrough pain. (C) 2003 by the American Pain Society.
引用
收藏
页码:291 / 297
页数:7
相关论文
共 27 条
[1]
Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life [J].
Ahmedzai, S ;
Brooks, D .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1997, 13 (05) :254-261
[2]
INCREASED UPTAKE OF TRANSDERMAL GLYCERYL TRINITRATE DURING PHYSICAL EXERCISE AND DURING HIGH AMBIENT-TEMPERATURE [J].
BARKVE, TF ;
LANGSETHMANRIQUE, K ;
BREDESEN, JE ;
GJESDAL, K .
AMERICAN HEART JOURNAL, 1986, 112 (03) :537-541
[3]
THE USE OF ULTRASOUND AS AN ENHANCER FOR TRANSCUTANEOUS DRUG-DELIVERY - PHONOPHORESIS [J].
BYL, NN .
PHYSICAL THERAPY, 1995, 75 (06) :539-553
[4]
Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain [J].
Christie, JM ;
Simmonds, M ;
Patt, R ;
Coluzzi, P ;
Busch, MA ;
Nordbrock, E ;
Portenoy, RK .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) :3238-3245
[5]
Breakthrough cancer pain:: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®) [J].
Coluzzi, PH ;
Schwartzberg, L ;
Conroy, JD ;
Charapata, S ;
Gay, M ;
Busch, MA ;
Chavez, J ;
Ashley, J ;
Lebo, D ;
McCracken, M ;
Portenoy, RK .
PAIN, 2001, 91 (1-2) :123-130
[6]
EFFECT OF EXERCISE AND HEAT EXPOSURE ON PERCUTANEOUS-ABSORPTION OF METHYL SALICYLATE [J].
DANON, A ;
BENSHIMON, S ;
BENZVI, Z .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 (01) :49-52
[7]
Long-term treatment of cancer pain with transdermal fentanyl [J].
Donner, B ;
Zenz, M ;
Strumpf, M ;
Raber, M .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1998, 15 (03) :168-175
[8]
PLASMA FENTANYL CONCENTRATIONS DURING TRANSDERMAL DELIVERY OF FENTANYL TO SURGICAL PATIENTS [J].
DUTHIE, DJR ;
ROWBOTHAM, DJ ;
WYLD, R ;
HENDERSON, PD ;
NIMMO, WS .
BRITISH JOURNAL OF ANAESTHESIA, 1988, 60 (06) :614-618
[9]
Influences of bathing and hot weather on the pharmacokinetics of a new transdermal clonidine, M-5041T [J].
Fujimura, A ;
Sasaki, M ;
Harada, K ;
Kumagai, Y ;
Ohashi, K ;
Ebihara, A .
JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (10) :892-896
[10]
THE TRANSDERMAL ADMINISTRATION OF FENTANYL IN THE TREATMENT OF POSTOPERATIVE PAIN - PHARMACOKINETICS AND PHARMACODYNAMIC EFFECTS [J].
GOURLAY, GK ;
KOWALSKI, SR ;
PLUMMER, JL ;
CHERRY, DA ;
GAUKROGER, P ;
COUSINS, MJ .
PAIN, 1989, 37 (02) :193-202